v3.25.4
Organization and description of business operations (Details Narrative)
 3 Months Ended 9 Months Ended
Nov. 22, 2023
USD ($)
$ / shares
shares
Nov. 20, 2023
$ / shares
shares
Oct. 30, 2023
Jun. 30, 2023
USD ($)
Nov. 17, 2022
USD ($)
Sep. 30, 2024
USD ($)
$ / shares
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
shares
Feb. 28, 2025
shares
Dec. 31, 2023
USD ($)
Nov. 30, 2023
$ / shares
Feb. 28, 2023
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Accumulated deficit           $ 59,597,347   $ 59,597,347     $ 52,029,741    
Net loss           876,642 $ 5,049,218 7,567,606 $ 12,369,252        
Net cash used in operating activities               5,003,200 8,151,230        
Amount of outstanding convertible promissory notes           $ 0   $ 0          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares           $ 0.25   $ 0.25          
Vox Nova Exclusive Pharmacy Distribution Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Collaborative arrangement exclusivity fees receivable       $ 2,000,000.0                  
Collaborative arrangement exclusivity fees receivable due upon signing agreement       500,000                  
Collaborative arrangement exclusivity fees receivable installments       $ 1,500,000                  
Distribution agreement exclusivity fees number of installments       four                  
Exclusive specialty benefit agreement term       1 year                  
Secondary Public Offering [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Payment of underwriter fees and commissions $ 600,000                        
Sale of stock offering costs 300,000                        
Common Stock [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Net loss                  
Reverse stock split ratio     1-for-17                    
Reverse stock split ratio     17                    
Common Stock [Member] | Purchase Agreemnet With PRV [Member] | Subsequent Event [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Common stock share issued | shares                   114,754,700      
Common Stock [Member] | Secondary Public Offering [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Number of shares authorized for sale in underwriting agreement | shares   5,384,615                      
Underwriting agreement price per share | $ / shares   $ 1.30                      
Sale of Stock, Consideration Received on Transaction $ 6,100,000                        
Number of warrants issued | shares   5,384,615                      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares   $ 1.30                   $ 1.30  
Common Stock [Member] | Over-Allotment Option [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Number of warrants issued | shares 215,385                        
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1.625                        
Convertible Promissory Note Issued 2023 [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Face amount of debt             $ 3,700,000   $ 3,700,000        
Convertible Promissory Note Issued 2023 [Member] | Lind Global Fund II LP [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Face amount of debt                         $ 3,700,000
Equity Purchase Agreement With Lincoln Park Capital Fund Llc [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Value of shares authorized for issuance         $ 20,000,000.0                
Term of agreement         30 months                
Number of shares issued | shares               0 200,000        
Proceeds from issuance of shares, net of fees                 $ 5,400,000        
Product [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenues               $ 0